A drug called WWL113 blocks inflammation through two separate mechanisms, not just one as originally thought. According to Gram Research analysis, WWL113 stops thromboxane A2 production—a harmful inflammatory substance that causes blood clots and vessel narrowing—at very low doses (0.1-0.2 micromoles). This dual-action discovery helps explain why the drug was so effective in previous obesity studies and shows scientists need to fully understand how medicines work before using them in humans.
Scientists studying a drug called WWL113 made an unexpected discovery: the medication doesn’t just work one way in the body—it actually blocks inflammation through two different pathways. The drug was designed to target a protein called CES1, but researchers found it also stops the production of thromboxane A2, a harmful inflammatory substance made by blood cells that can contribute to heart disease. This accidental discovery helps explain why WWL113 worked so well in previous studies with obese mice, and it shows how important it is to fully understand how medicines work in our bodies.
Key Statistics
A 2026 laboratory study found that WWL113 reduced thromboxane A2 production by 50% at concentrations of 0.1-0.2 micromoles in human immune cells, revealing an unexpected anti-inflammatory mechanism beyond its intended target.
In specially engineered cells overexpressing thromboxane A2 synthase, WWL113 was approximately 1000 times more potent, achieving 50% inhibition at 226 nanomoles, demonstrating the drug’s strong direct effect on this inflammatory enzyme.
A comparison study showed that WWL229, a similar CES1 inhibitor drug, had no effect on thromboxane A2 production in either cell lysates or living cells, indicating that off-target effects are specific to individual drugs rather than shared across drug families.
The Quick Take
- What they studied: Whether a drug called WWL113 affects multiple inflammation-causing proteins in the body, not just the one it was designed to target
- Who participated: Laboratory experiments using human immune cells (THP-1 monocytes), specially engineered cells (COS-7 cells), and previous studies in obese mice
- Key finding: WWL113 successfully blocked thromboxane A2 production at very low doses (0.1-0.2 micromoles), suggesting it works against inflammation through multiple mechanisms
- What it means for you: This research helps scientists understand why WWL113 was so effective in previous studies. However, this is early laboratory research—it doesn’t mean the drug is ready for human use yet. Scientists now recommend using a different drug (WWL229) if they want to study only the CES1 pathway
The Research Details
Researchers conducted laboratory experiments to test whether WWL113 affects thromboxane A2 synthase (TBXAS1), a protein responsible for making thromboxane A2—a harmful inflammatory substance. They used human immune cells grown in dishes and added the drug at different concentrations to see what happened. They measured how much thromboxane A2 was produced at each drug dose. They also tested a similar drug called WWL229 to see if it had the same effect. Finally, they used specially engineered cells that produced extra TBXAS1 protein to confirm that WWL113 directly blocks this enzyme.
The researchers measured the results using a sophisticated technique called LC-MS/MS, which can detect and measure tiny amounts of chemical substances. This allowed them to precisely track how much thromboxane A2 (measured as its stable form, thromboxane B2) was produced under different conditions. They calculated the IC50 value—the drug concentration needed to reduce thromboxane A2 production by half—which helps scientists understand how potent the drug is.
Understanding how drugs work in the body is crucial for developing safe and effective medicines. When a drug affects multiple targets (called ‘off-target effects’), it can explain both beneficial and harmful effects. This discovery helps explain why WWL113 worked so well in previous obesity studies and shows that scientists need to carefully test all the ways a drug might work before using it in humans.
This is controlled laboratory research using established cell lines and measurement techniques. The findings were confirmed in multiple cell types (human monocytes and engineered cells), which strengthens the conclusions. However, this is early-stage research conducted in dishes and test tubes, not in living animals or humans. The lack of a specified sample size for some experiments and the focus on laboratory conditions rather than real-world use are important limitations to consider.
What the Results Show
When researchers added WWL113 to human immune cells, it significantly reduced thromboxane A2 production. The drug achieved a 50% reduction at very low concentrations (0.1-0.2 micromoles). Interestingly, when WWL113 blocked thromboxane A2, it actually increased another inflammatory substance called prostaglandin E2, suggesting the drug shifts the balance between different inflammatory pathways rather than simply reducing all inflammation.
When the researchers tested a similar drug called WWL229, it had no effect on thromboxane A2 production. This is important because it shows that the ability to block thromboxane A2 is specific to WWL113 and not a general property of all CES1 inhibitors. In specially engineered cells that produced extra thromboxane A2 synthase protein, WWL113 was even more potent, blocking the enzyme at a concentration of 226 nanomoles—about 1000 times more powerful than in regular cells.
The research revealed that WWL113 affects the balance of inflammatory substances in cells. While it reduces thromboxane A2 (which causes blood clots and vessel narrowing), it increases prostaglandin E2 (which has different inflammatory effects). This suggests that blocking one enzyme can have cascading effects on related inflammatory pathways. The fact that WWL229 doesn’t affect thromboxane A2 production indicates that different CES1 inhibitors have different off-target effects, meaning scientists cannot assume all drugs in the same family work identically.
According to Gram Research analysis, this finding helps explain results from earlier studies where WWL113 showed strong anti-inflammatory effects in obese mice. Previous researchers may have attributed all of WWL113’s benefits to blocking CES1, but this study shows that blocking thromboxane A2 synthase likely contributed significantly to those benefits. Thromboxane A2 is well-known to promote blood clots and narrow blood vessels, so blocking it could help prevent heart disease—a major benefit in obese individuals who are at high risk.
This research was conducted entirely in laboratory settings using cells grown in dishes, not in living organisms. The study doesn’t tell us whether these effects occur in human bodies or at what doses. The researchers didn’t test whether blocking thromboxane A2 with WWL113 actually prevents heart disease or other health problems. Additionally, the study doesn’t explain the exact mechanism of how WWL113 blocks thromboxane A2 synthase—only that it does. Finally, because this is early-stage research, we don’t know about potential side effects or whether the drug would be safe for human use.
The Bottom Line
This research is important for scientists developing new drugs, but it’s not yet ready to inform patient care. The recommendation from the researchers is clear: scientists should use WWL229 instead of WWL113 if they want to study only the CES1 pathway, since WWL113 affects multiple targets. For the general public, this research suggests that understanding how drugs work through multiple pathways may be important for their effectiveness, but human studies are needed before any recommendations can be made. Confidence level: High for laboratory findings; Low for real-world human applications.
This research matters most to pharmaceutical scientists and drug developers working on inflammation and heart disease treatments. It’s also relevant to researchers studying obesity and metabolic disease. Patients with heart disease, obesity, or inflammatory conditions should not assume this drug is ready for them—much more research is needed. Healthcare providers should be aware that drugs may have multiple effects in the body beyond their intended target.
This is fundamental research that may eventually lead to new treatments, but the timeline is uncertain. Typically, a discovery like this would require 5-10+ years of additional research before human trials could begin, and several more years before a drug might become available to patients. This is not a treatment that will be available soon.
Frequently Asked Questions
Does WWL113 work better than aspirin for preventing blood clots?
This research doesn’t compare WWL113 to aspirin. Both drugs may block thromboxane A2, but WWL113 is still in early laboratory testing. Aspirin is proven safe and effective for heart disease prevention. Talk to your doctor before considering any new treatments.
Can I take WWL113 to reduce inflammation in my body?
WWL113 is not available for human use. This is early laboratory research conducted in cells and dishes. Many years of additional testing would be needed before it could be considered for patients. Never seek out experimental drugs without medical supervision.
What is thromboxane A2 and why does blocking it matter?
Thromboxane A2 is a chemical made by blood cells that causes blood clots and narrows blood vessels, contributing to heart attacks and strokes. Blocking it may help prevent these events, which is why aspirin (which blocks thromboxane A2) is used to prevent heart disease.
Why did scientists recommend using WWL229 instead of WWL113?
WWL113 affects multiple targets in the body, not just CES1. If researchers want to study only CES1, WWL229 is better because it doesn’t have this off-target effect. This prevents confusion about which protein is actually responsible for observed effects.
Could this research lead to new heart disease treatments?
Possibly. Understanding how drugs affect thromboxane A2 production could help develop better anti-inflammatory and heart-protective medications. However, this is very early research—many more studies in animals and humans would be needed before new treatments reach patients.
Want to Apply This Research?
- While this research doesn’t directly apply to consumer health apps yet, users interested in inflammation management could track inflammatory markers they measure through their doctor (like C-reactive protein or blood clotting markers) alongside lifestyle factors like diet and exercise to see personal patterns
- Users could use an app to monitor and log foods and activities known to affect thromboxane A2 production, such as omega-3 intake, aspirin use (which blocks thromboxane A2), and cardiovascular exercise, while tracking any changes in inflammation-related symptoms
- Set up monthly check-ins to review trends in inflammation markers and cardiovascular risk factors with a healthcare provider, using the app to maintain consistent records of diet, supplements, medications, and any heart-health related symptoms or measurements
This research describes early-stage laboratory findings about how a drug affects inflammation-related proteins. These results were obtained in cells grown in dishes, not in living humans. WWL113 is not approved for human use and is not available as a treatment. This article is for educational purposes only and should not be interpreted as medical advice. Do not attempt to obtain or use experimental drugs. Anyone interested in inflammation management or heart disease prevention should consult with their healthcare provider about proven, safe, and effective treatment options. This research does not replace professional medical diagnosis, treatment, or advice.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.